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IMPORTANCE Despite being characterized as a disorder of language production,
nonfluent/agrammatic variant primary progressive aphasia (nfvPPA) is frequently associated
with auditory symptoms. However, to our knowledge, peripheral auditory function has not
been defined in this condition.
OBJECTIVE To assess peripheral hearing function in individuals with nfvPPA compared
with healthy older individuals and patients with Alzheimer disease (AD).
DESIGN, SETTING, AND PARTICIPANTS This cross-sectional single-center studywas conducted
at the Dementia Research Centre of University College London between August 2015 and
July 2018. A consecutive cohort of patients with nfvPPA and patients with ADwere
compared with healthy control participants. No participant had substantial otological
or cerebrovascular disease; all eligible patients fulfilling diagnostic criteria and able to comply
with audiometry were included.
MAIN OUTCOMES ANDMEASURES Wemeasuredmean threshold sound levels required to
detect pure tones at frequencies of 500, 1000, 2000, 4000, and 6000Hz in the left and
right ears separately; these were used to generate better-ear mean and worse-ear mean
composite hearing threshold scores and interaural difference scores for each participant.
All analyses were adjusted for participant age.
RESULTS We studied 19 patients with nfvPPA (9 female; mean [SD] age, 70.3 [9.0] years),
20 patients with AD (9 female; mean [SD] age, 69.4 [8.1] years) and 34 control participants
(15 female; mean [SD] age, 66.7 [6.3] years). The patients with nfvPPA had significantly
higher scores than control participants on better-ear mean scores (patients with nfvPPA:
mean [SD], 36.3 [9.4] decibels [dB]; control participants: 28.9 [7.3] dB; age-adjusted
difference, 5.7 [95% CI, 1.4-10.0] dB; P = .01) and worse-ear mean scores (patients with
nfvPPA: 42.2 [11.5] dB; control participants: 31.7 [8.1] dB; age-adjusted difference, 8.5
[95% CI, 3.6-13.4] dB; P = .001). The patients with nfvPPA also had significantly higher
better-ear mean scores than patients with AD (patients with AD: mean [SD] 31.1 [7.5] dB;
age-adjusted difference, 4.8 [95% CI, 0.0-9.6] dB; P = .048) and worse-ear mean scores
(patients with AD: mean [SD], 33.8 [8.2] dB; age-adjusted difference, 7.8 [95% CI, 2.4-13.2]
dB; P = .005). The difference scores (worse-ear meanminus better-ear mean) were
significantly higher in the patients with nfvPPA (mean [SD], 5.9 [5.2] dB) than control
participants (mean [SD], 2.8 [2.2] dB; age-adjusted difference, 2.8 [95% CI, 0.9-4.7] dB;
P = .004) and patients with AD (mean [SD], 2.8 [2.1] dB; age-adjusted difference, 3.0
[95% CI, 0.9-5.1] dB; P = .005).
CONCLUSIONS AND RELEVANCE In this study, patients with nfvPPA performedworse on
pure-tone audiometry than healthy older individuals or patients with AD, and the difference
was not attributable to age or general disease factors. Cases of nfvPPAwere additionally
associated with increased functional interaural audiometric asymmetry. These findings
suggest conjoint peripheral afferent andmore central regulatory auditory dysfunction
in individuals with nfvPPA.
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N onfluent/agrammatic variant primary progressiveaphasia (nfvPPA) is characterized as a disorder oflanguageproduction.1Hearing inpeoplewithnfvPPA
is not well characterized, but patients often experience
difficulty followingnoisy and/or accented speech,worddeaf-
ness, impaired recognition of voices and environmental
sounds, and other symptoms potentially susceptible to audi-
tory dysfunction.1-5 Besides its implications for the neurobi-
ology and diagnosis of primary progressive aphasia, charac-
terization of auditory dysfunction in patients with nfvPPA
might help elucidate the potentiating role of hearing impair-
ment in other neurodegenerative disorders (eg, Alzheimer
disease [AD]).2,6 Here we assessed peripheral hearing using
pure-toneaudiometry inpatientswithnfvPPAcomparedwith
healthy control participants and patients with AD.
Methods
Participant Characteristics
WerecruitedpatientswithnfvPPA,patientswithAD, andcon-
trol participants between August 2015 and July 2018. All pa-
tients fulfilled diagnostic criteria,7 supported by neuropsy-
chological assessment andbrainmagnetic resonance imaging
(eMethods in the Supplement). No participant had a history
of substantial otological disease or major comorbid cerebro-
vascular burden.
EthicalapprovalwasgrantedbytheUniversityCollegeLon-
donandNationalHospital forNeurologyandNeurosurgery re-
search ethics committees.All participants gave informedcon-
sent consistent with Declaration of Helsinki guidelines.
Audiometry Procedure
We adapted a standard clinical audiometry protocol8 assess-
ing frequencies 500, 1000, 2000, 4000, and 6000 Hz (de-
tails in theSupplement).Theparticipant’smeanthreshold level
for detecting each frequency was recorded in each ear.
Data Analyses
Demographicandclinicalcharacteristicswerecomparedbetween
groups using analysis of variance and Fisher exact tests. Audi-
ometrydatawere analyzedbyadaptingapreviouslydescribed
protocol.6Foreachparticipant, composite left-earmean, right-
earmean, better-earmean (BEM), andworse-earmean (WEM)
thresholdandinterauraldifferencescoreswerecalculatedacross
meanthresholdlevelsforall frequencies.Thesescoreswerecom-
paredbetweengroupsusinganalysisofcovariancemodels,with
participant age as a covariate; pairwise groupdifferenceswere
assessedusingplannedcomparisons that alsoadjusted for age.
We conducted a separate analysis relaxing normality and ho-
moscedasticityassumptions tocheck robustness (eTable in the
Supplement). Fordescriptivepurposes,wecreated categorical
scores for eachcompositemean,with scoresof20 to40dBcat-
egorizedasmildhearing loss, andscoresgreater than41dBcat-
egorized asmoderate hearing loss.8
WeusedSpearmanρtoassessassociationsbetweenageand
bothBEMandWEMscoresacross theentirecohort, andaseries
ofpartial correlationanalyses (controlling for age) assessingas-
sociationsbetweenBEMandWEMscoresandclinicalduration,
severity (viaMini-MentalStateExamination[MMSE]score),and
nonverbalexecutivefunction(WechslerAbbreviatedScaleof In-
telligence [WASI]matrix reasoning score) in the combined pa-
tient cohort; andwithmeasuresof speechapraxia (polysyllabic
wordrepetitionscore)andagrammatism(writtensentencecon-
struction score) in thenfvPPAgroup.Anα level of .05wasused
asthestatistical significancethreshold.Datawereanalyzedwith
Stata version 14 (StataCorp).
Results
Nineteen patients with nfvPPA, 20 patients with AD, and 34
control participants participated (Table 1). The control partici-
pantshadayoungermean (SD) age (66.7 [6.3] years) thanboth
patientgroups (nfvPPAgroup, 70.3 [9.0];ADgroup,69.4 [8.1]),
although the differences were not statistically significant
(P = .19;Table 1). The inclusionof sexeswasvery similar across
groups (control participants, 15 of 34 female [44%]; nfvPPA
group, 9 of 19 female [47%]; AD group, 9 of 20 female [45%];
FisherexactP > .99).Therewerenostatistically significantdif-
ferences between patient groups in mean (SD) symptom du-
ration (ADgroup,6.6 [4.0]years; nfvPPAgroup,4.9 [2.1] years;
P = .10),MMSEscore (ADgroup, 18.6 [5.9]; nfvPPAgroup, 22.6
[7.1] points; P = .06), or executive function test result (AD
group, 10.6 [6.6]; nfvPPA group, 13.9 [9.0]; P = .21).
Therewasevidenceofdifferencesamongthe3groups inau-
diologic function in left-earmean scores (control participants,
30.3 [7.2]dB;ADgroup, 32.7 [7.9]dB;nfvPPAgroup, 38.2 [10.2]
dB;P = .02),right-earmeanscores(controlparticipants,30.4[8.5]
dB;ADgroup,32.4[8.0]dB;nfvPPAgroup,39.6[11.7]dB;P = .01),
BEMscores(controlparticipants,28.9[7.3]dB;ADgroup,31.1[7.5]
dB;nfvPPAgroup,36.3 [9.4]dB;P = .03), andWEMscores (con-
trol participants, 31.4 [8.1] dB; ADgroup, 33.8 [8.2] dB; nfvPPA
group, 42.2 [11.5] dB;P = .002) (Table 2;Figure, A). Composite
audiometric threshold scores were significantly higher in the
nfvPPAgroupthancontrolparticipants(age-adjusteddifferences:
left-earmeanscore,6.3 [95%CI, 1.9-10.8]dB;P = .006; right-ear
mean score, 7.2 [95% CI, 2.2-12.1] dB; P = .005; BEM score, 5.7
[95%CI, 1.4-10.0]dB;P = .01;WEMscore,8.5 [95%CI, 3.6-13.4]
dB;P = .001) and inpatientswithAD(age-adjusteddifferences:
left-earmeanscore, 5.1 [95%CI,0.2-10.0]dB;P = .04; right-ear
mean score, 6.7 [95% CI, 1.2-12.1] dB; P = .02; BEM score, 4.8
Key Points
Question What is the status of peripheral hearing in patients
with nonfluent/agrammatic variant primary progressive aphasia
(nfvPPA)?
Findings Patients with nfvPPA performedworse on pure-tone
audiometry than healthy older individuals or patients with
Alzheimer disease, after controlling for age and general disease
factors. In addition, these patients showed increased functional
interaural audiometric asymmetry.
Meaning Auditory system involvement in patients with nfvPPA
is more substantial than previously recognized.
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[95%CI,0.0-9.6]dB;P = .048;WEMscore,7.8[95%CI,2.4-13.2]
dB;P = .005).Therewerenosignificantaudiometricdifferences
between the control participants and patients with AD (age-
adjusteddifferences: left-earmeanscore, 1.2 [95%CI,−3.1 to5.6]
dB; P = .57; right-ear mean score, 0.5 [95% CI, −4.3 to 5.4] dB;
P = .83; BEM score, 0.9 [95% CI, −3.3 to 5.1] dB; P = .68; WEM
score,0.7 [95%CI,−4.0to5.5]dB;P = .77).Audiograms(Figure,
B andC) showed elevated thresholds across frequencies in the
nfvPPA group comparedwith the control and AD groups but a
similar overall frequency sensitivity profile in all groups.
Of 34 control participants, 4 each had moderate hearing
loss in the left ear (12%) and the right ear (12%). Of the 20 par-
ticipants with AD, 5 had moderate hearing loss in the left ear
(25%) and 3 in the right ear (16%). Of 19 patientswith nfvPPA,
moderatehearing losswaspresent in the left ear in 7 individu-
als (37%) and in the right ear in 7 individuals (39%).
Therewasalsoevidenceofdifferencesamong the3groups
inWEM-BEM difference scores (mean (SD): control group, 2.7
[2.2] dB; AD group, 2.8 [2.1] dB; nfvPPA group, 5.9 [5.2] dB;
P = .006), thesebeing significantlyhigher in thenfvPPAgroup
Table 1. Demographic, Clinical, and Audiometric Characteristics of Participant Groups
Characteristic
Participants, No. (%)
Control Participants Alzheimer Disease nfvPPA
Total 34 20 19
Male 19 (56) 11 (55) 10 (53)
Age, mean (SD), y 66.7 (6.3) 69.4 (8.1) 70.3 (9.0)
Symptom duration, mean (SD), y NA 6.6 (4.0) 4.9 (2.1)
Speech apraxia NA 0 19 (100)
Expressive agrammatism NA 0 12 (63)
Parkinsonian features NA 0 11 (58)a
Supranuclear gaze palsy NA 0 9 (47)a
Neuropsychological scores, mean (SD)
Mini-Mental State Examination scoreb NA 18.6 (5.9) 22.6 (7.1)
Wechsler Abbreviated Scale of Intelligence matricesc 26.1 (4.0) 10.6 (6.6) 13.9 (9.0)
Word repetitiond 44.4 (1.2) NA 33.8 (9.5)
Expressive agrammatisme 24.9 (0.4) NA 17.5 (8.2)
Abbreviations: NA, not applicable; nfvPPA, patient group with
nonfluent/agrammatic variant primary progressive aphasia.
a Ten cases fulfilled current consensus diagnostic criteria suggesting underlying
tauopathy: 9 with probable or definite progressive supranuclear palsy
(Hoeglinger criteria) and 1 with probable corticobasal degeneration
(Armstrong criteria). Of the remaining 9 patients with nfvPPA, 3 had
confirmed pathological genetic mutations causing TDP-43 pathology
(2 with progranulin and 1 with C9orf72). Hearing scores did not differ
significantly between subgroups of patients with nfvPPAwith and without
probable or definite tauopathy (by analysis of covariancemodels adjusting
for age: left-ear mean score, −3.4 [95% CI, −15.1 to 8.3]; P = .55; right-ear mean
score, 5.9 [95% CI, −8.1 to 20.0]; P = .38; better-ear mean score, 3.5 [95% CI,
−7.8 to 14.7]; P = .52; worse-ear mean score, 1.2 [95% CI, −13.0 to 15.3];
P = .86).
b TheMini-Mental State Examination is on a scale of 30 points.
c Wechsler Abbreviated Scale of Intelligencematrices data were missing for 1
control participant and 1 participant with AD; this test is on a scale of 32 points.
dWord repetition data were missing for 4 control participants and 6 participants
with nfvPPA; this test is on a scale of 45 points.
e Expressive agrammatism data weremissing for 4 control participants
and 6 participants with nfvPPA; this test is on a scale of 25 points.
Table 2. Audiometry Results for Participant Groupsa
Hearing Measurement
Scores, Mean (SD), dB
Mean (SD) Differences (95% CI)
P Value
Control
Participants
Participants
With Alzheimer
Disease
Participants
with nfvPPAb
Participants with
Alzheimer Disease vs
Control Participants
Participants with
nfvPPA vs Participants
With Alzheimer Disease
Participants With
nfvPPA vs Participants
With Alzheimer Disease
Left ear 30.3 (7.2) 32.7 (7.9) 38.2 (10.2) 1.2 (−3.1 to 5.6) 6.3 (1.9-10.8) 5.1 (0.2-10.0) .02
Right earc 30.4 (8.5) 32.4 (8.0) 39.6 (11.7) 0.5 (−4.3 to 5.4) 7.2 (2.2-12.1) 6.7 (1.2-12.1) .01
Left-ear mean–right-ear
mean differencec
−0.1 (3.6) 0.2 (3.6) −0.7 (7.9) 0.5 (−2.3 to 3.4) −0.2 (−3.1 to 2.8) −0.7 (−4.0 to 2.6) .90
Better ear 28.9 (7.3) 31.1 (7.5) 36.3 (9.4) 0.9 (−3.3 to 5.1) 5.7 (1.4-10.0) 4.8 (0.0-9.6) .03
Worse earc 31.7 (8.1) 33.8 (8.2) 42.2 (11.5) 0.7 (−4.0 to 5.5) 8.5 (3.6-13.4) 7.8 (2.4-13.2) .002
Worse-ear
mean–better-ear
mean differencec
2.7 (2.2) 2.8 (2.1) 5.9 (5.2) −0.2 (−2.0 to 1.7) 2.8 (1.0-4.7) 3.0 (0.9-5.1) .006
Abbreviation: nfvPPA, patient group with nonfluent/agrammatic variant
primary progressive aphasia.
a Peripheral hearing composite scores for each participant were calculated by
taking themean threshold level required to hear tones at frequencies of 500,
1000, 2000, 4000, and 6000Hz. Results from a separate analysis that
relaxed normality and homoscedasticity assumptions and found similar results
(eTable in the Supplement).
bAll values except the left-ear–right-ear mean difference score were
significantly worse in participants with nfvPPA than both of the other
participant groups.
c Data for 1 participant with Alzheimer disease and 1 participant with nfvPPA
were only available for the left ear.
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than in control participants (age-adjusted difference, 2.8
[95% CI, 0.9-4.7] dB; P = .004) and patients with AD (3.0
[95%CI,0.9-5.1]dB;P = .005).Worse-earmean–better-earmean
(SD) difference scores were comparable in the AD and control
groups (age-adjusted difference, −0.2 [95%CI, −2.0 to 1.7] dB;
P = .85).Therewasnoevidenceofdifferencesamonggroups in
left-ear mean–right-ear mean (SD) difference scores (control
group,−0.1 [3.6]dB;ADgroup,0.2 [3.6]dB;nfvPPAgroup,−0.7
[7.9]dB;P = .90).Findingsfromtheparallelanalysisrelaxingnor-
malityandhomoscedasticityassumptionsweresubstantiallyun-
changed (eTable 1 in the Supplement).
Across thecombinedparticipantcohort, agewasassociated
withWEMscores (ρ = 0.48;P < .001) andBEMscores (ρ = 0.46;
P < .001).Across thepatientcohort,afteradjustingforage, there
were no significant effects of disease duration, MMSE, WASI
matrices, or language production scores on WEM scores
(duration partial r = −0.18; P = .30; MMSE, partial r = 0.04;
P = .82;WASImatrices,partialr = 0.08;P = .66;wordrepetition,
partialr = −0.34;P = .30;sentenceconstruction,partialr = −0.45;
P = .17)orBEMscores(duration,partialr = −0.10;P = .56;MMSE,
partial r = 0.10;P = .55;WASImatrices, partial r = 0.21;P = .23;
wordrepetition,partialr = −0.12;P = .72;sentenceconstruction,
partial r = −0.32;P = .34).
Discussion
In this analysis,wepresent evidence thatpatientswithnfvPPA
performworseonpure-toneaudiometry thanhealthyolder in-
dividuals or patients with AD. These data suggest that this is
not attributable to age or general disease factors. Moreover,
nfvPPA was associated with increased interaural functional
asymmetry, not lateralized to the right ear or left ear. The role
of the auditory system in this language-led dementia has not
been defined. These findings suggest that auditory pathway
involvement in nfvPPA ismore significant than generally rec-
ognized, corroborating the diverse hearing alterations (ex-
tending to environmental sounds and music) previously re-
ported in these patients1-5,9-11 and proposed to contribute to
the pathogenesis of nfvPPA.4,10
While this study has not defined the neural substrate for
audiologic impairment innfvPPA, thereare several candidates.
Impairedpure-toneaudiometryusually signifiesperipheral au-
ditory dysfunction; most cases of nfvPPA are underpinned by
tauopathy(encompassingcorticobasaldegenerationandprogres-
sive supranuclear palsy1; Table 1), andbrainstemand subcorti-
calpathways, includingauditorypathways,arevulnerabletothis
pathology.However, involvementofperipheral auditoryaffer-
ents in tauopathies does not necessarily produce audiologic
deficits.12 Audiologic impairment in individuals with nfvPPA
mightadditionally reflect involvementofcerebral integrativeor
brainstemefferent regulatoryprocesses, suchas those involved
in auditory target detection.13,14 Any suchdysregulatory effect
wouldtendtobeamplified inbackgroundnoise,consistentwith
clinicalobservations.1,2Thefindingof increasedinteraural func-
tionalasymmetry in individualswithnfvPPAisunlikely tobeat-
tributabletocochlearorauditorynervepathologyandimplicates
more central pathways, although itsmechanism remains to be
established.
Future work should address the mechanism of audio-
logic impairment in individualswithnfvPPAinassociationwith
cognitive and speech output functions in this syndrome and
effectsonpatients’daily lives.Auditoryprocessing in thesepa-
tients shouldbe furthercharacterized,bothphysiologically (in-
cluding tympanometry, otoacoustic emissions, brainstemau-
ditory evokedpotentials, dichotic listening, andother central
hearing tasks)andneuroanatomically (includingstructural and
functional neuroimaging techniques) to establish the nature
and locus of their hearing impairment.
Conclusions
Consistent with recent work,2,4,10 these findings suggest that
patients with nfvPPA have a disorder of communication sig-
nal processing that extends beyond neurolinguistic impair-
ment; itmay be timely to reevaluate the progressive aphasias
from this fresh perspective. As a paradigm of selective neural
system degeneration, nfvPPA could serve as a model disor-
Figure. Pure-Tone Audiometry Scores Across Participant Groups
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der for interpreting the interplayofperipheralhearingandcog-
nitive function in neurodegenerative disease and evaluating
physiologically informed hearing and communication thera-
pies in people with dementia. These could include interven-
tions to improve the fidelity of auditory signal processing in
noisyenvironmentsandharness residualplasticity in thedam-
aged auditory system, an approach that shows early promise
in patients with AD.15
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